[CLSTR]
< Back to situation

[REVISION HISTORY]

Clinical applications and access of CAR-T cell therapy

Updated 14 times since CLSTR started tracking revisions of this situation.

What changed

2026-10-04 22:36 UTC → 2026-10-05 20:14 UTC · added removed

CAR-T cell therapy continues to expand its clinical utility across oncology and autoimmune diseases. In oncology, the therapy is transforming treatment for aggressive lymphomas and resistant blood cancers. A significant milestone was highlighted in the CARE study, where a three-year-old boy achieved complete remission from metastatic hepatoblastoma using T cells modified to target the Glypican-3 (GPC3) protein. This experimental treatment allowed the patient to remain disease-free for 12 months without severe systemic toxicities. Recent data regarding Johnson & Johnson’s cilta-cel (ciltacabtagene-autoleucel) has demonstrated long-term efficacy in treating multiple myeloma. In a subset of the phase 2 Cartitude-2 study, myeloma, with 50 percent of patients with relapsed or refractory multiple myeloma remained in a phase 2 study remaining alive without disease progression for at least five years following a single infusion, without requiring maintenance therapy. However, safety concerns persist. years. Research published in Nature Medicine has identified enterocolitis—inflammation of the small intestine is now broadening to include more diverse patient populations and colon—as a rare but significant complication following anti-BCMA specific malignancies. Oncology specialists are evaluating CAR T therapy. This toxicity appears to be an immune-mediated response caused T-cell therapy and targeted agents for chronic lymphocytic leukemia (CLL). Furthermore, investigations by the persistence of CAR T cells within AIDS Malignancy Consortium and the intestinal mucosa, leading to prolonged inflammatory remodeling. Researchers Center for International Blood and Marrow Transplant Research are investigating examining the use safety of JAK signaling pathway inhibitors CAR T-cell therapy and bispecific antibodies in patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma. Preliminary matched cohort analysis suggests that cytokine release syndrome may occur less frequently in HIV-positive patients receiving CD19-directed CAR T-cell therapy compared to manage this condition. The scope of the technology those without HIV. Clinical access is also broadening. expanding geographically and therapeutically. In Mexico, Cofepris has authorized the CARLLA-B1 protocol, the first domestic clinical trial, the CARLLA-B1 protocol, trial to evaluate MB-CART19 therapy for adults with relapsed or refractory acute lymphoblastic leukemia. Additionally, researchers at the Yale School of Medicine are exploring the use of CAR-T applications for as a ‘living drug’ to target the underlying causes of severe autoimmune conditions, such as lupus, multiple sclerosis, and scleroderma, utilizing the therapy as a ‘living drug’ to target underlying disease causes. scleroderma.

Versions

  1. 2026-10-05 20:14 UTC Clinical applications and access of CAR-T cell therapy
  2. 2026-10-04 22:36 UTC Clinical applications and access of CAR-T cell therapy
  3. 2026-09-28 17:34 UTC Clinical applications and access of CAR-T cell therapy
  4. 2026-09-25 00:11 UTC Clinical applications and access of CAR-T cell therapy
  5. 2026-09-24 11:03 UTC Clinical applications and access of CAR-T cell therapy
  6. 2026-09-21 07:19 UTC Clinical applications and access of CAR-T cell therapy
  7. 2026-09-18 10:44 UTC Clinical applications and access of CAR-T cell therapy
  8. 2026-09-16 23:12 UTC Clinical applications and access of CAR-T cell therapy
  9. 2026-09-15 10:35 UTC Clinical applications and access of CAR-T cell therapy
  10. 2026-09-15 09:50 UTC Clinical applications and access of CAR-T cell therapy
  11. 2026-09-15 06:01 UTC Clinical applications and access of CAR-T cell therapy
  12. 2026-09-09 01:42 UTC Clinical applications and access of CAR-T cell therapy
  13. 2026-09-08 11:02 UTC Clinical applications of CAR-T cell therapy
  14. 2026-09-02 23:03 UTC Clinical applications of CAR-T cell therapy
  15. 2026-08-11 02:43 UTC Clinical applications of CAR-T cell therapy

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.